For years, a quiet fear has shadowed pregnant women who depend on antidepressants: the worry that the medication keeping them stable might somehow alter the developing mind of their child. A landmark meta-analysis published in The Lancet Psychiatry, drawing on data from more than 600,000 medicated pregnancies, now offers what science rarely delivers so cleanly — reassurance grounded in scale. When researchers separated the effect of the drugs from the genetic and psychiatric inheritance of the parents themselves, the suspected link to autism and ADHD dissolved, suggesting that untreated matern
El Nacional
· May 15, 2026
· health
· 2 min read
High
Sourcing: Verified
Major study finds no causal link between pregnancy antidepressants and autism
◉
Technology
2554 related articles
Usuarios de PayPal pueden obtener un año gratis de Perplexity Pro
LA RAZÓN · 99% match
Los 'Siete Magníficos' asiáticos: TSMC, Samsung y compañía dominan mer…
Expansión · 99% match
Anthropic presenta Claude Opus 4.7 con mejoras sustanciales en ingenie…
Digital Trends Español · 99% match
¿Sobrevivirá el teléfono inteligente a la era de la inteligencia artif…
Diario Gestión · 99% match
MANGOS: el nuevo acrónimo de Wall Street que arrasa en la inversión en…
El Economista · 99% match
Related Coverage
El Ecosistema Startup · Aug 22
Cigna invierte US$100M en IA para automatizar farmacias specialty en medio de presión regulatoria
Cigna lanza Pharmacy Forward, un programa de farmacia specialty impulsado por IA con inversión de US$100 millones hasta …
El Ecosistema Startup · Aug 22 Pew: 35% del contenido web nuevo ya está escrito por IAPew Research Center revela que 35% de las páginas web publicadas desde noviembre de 2022 muestran señales claras de auto…
El Ecosistema Startup · Aug 22 El 98% ve al SO como pieza clave para asegurar la cadena de suministro open sourceInforme de Canonical revela que el 98% considera el SO clave para seguridad open source, pero la fragmentación de herram…
DPL News · Aug 22 Telefónica renueva su Plan de Acción Climática con metas hacia cero emisiones en 2040Telefónica refuerza su compromiso ambiental con un renovado Plan de Acción Climática 2026 que busca alcanzar cero emisio…
Bias & Framing
⚖
Article presents reassuring findings from a large meta-analysis with minimal bias, though it could better acknowledge remaining uncertainties and alternative explanations.
Bias Direction
center
Confidence
MED
Scientific authority framing - relies heavily on study credibility and expert consensus to present reassuring conclusions about antidepressant safety during pregnancy
pruebas tranquilizadoras (reassuring evidence)
mejor evidencia (best evidence)
descarta vinculo causal (rules out causal link)
Perspectives from pregnant women or patient advocacy groups regarding medication decisions
Discussion of limitations or caveats in meta-analysis methodology
Alternative viewpoints from researchers who found associations in previous studies
Perspectives on the complexity of disentangling medication effects from underlying maternal mental health conditions
Information about ongoing monitoring or post-market surveillance
Geopolitical Impact
🌎
Medical research finding on antidepressant safety has no geopolitical implications; this is a public health matter without international power dynamics.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Meta-analysis of 600,000+ pregnancies finds no causal link between common antidepressants and autism/ADHD, reducing medical liability concerns and supporting continued psychiatric treatment during pregnancy.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Antidepressant Manufacturing
Healthcare/Mental Health Services
Insurance/Medical Liability
Obstetrics and Gynecology
Psychiatric Care
Pregnant women with depression/anxiety can continue antidepressant treatment with greater confidence, reducing treatment discontinuation and associated maternal health risks; reduces parental anxiety about medication safety and potential out-of-pocket costs for alternative treatments.
Likely to strengthen clinical guidelines recommending antidepressant continuation during pregnancy; may reduce litigation risk for pharmaceutical companies and healthcare providers; could influence insurance coverage policies to maintain antidepressant access for pregnant patients; potential regulatory clarification of pregnancy safety labeling.